FDA approves new form of sevelamer for chronic kidney disease
The FDA has approved a new form of sevelamer, a phosphatebinder used to treat patients with chronic kidney disease (CKD) who are on dialysis. Renvela (sevelamer carbonate) differs from its predecessor Renagel (sevelamer HCl) in that it offers the added benefit of a carbonate buffer, according to manufacturer Genzyme Corp. Both products are calciumfree and are not systemically absorbed; however, in clinical trials comparing the two agents, Renvela (see http://www.renvela.com/) was more likely to maintain bicarbonate levels within the recommended National Kidney Foundation's Kidney Disease Outcomes Quality Initiative, or KDOQI, ranges in addition to controlling serum phosphorus levels. It also had a lower incidence of GI adverse effects. Genzyme expects to launch Renvela during the first quarter of 2008 in 800-mg tablets.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.